JHL Biotech to Build KUBio Modular Facility - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

JHL Biotech to Build KUBio Modular Facility


GE Healthcare Life Sciences announced that it will build a KUBio modular biopharmaceutical factory in China for JHL Biotech, a provider of biopharmaceutical process development and manufacturing services. The site for the new factory, which will be operational beginning early 2015, is the Biolake Science Park in Wuhan, China.

The turnkey approach involves the on-site assembly of pre-made modules. GE will project-manage the build and members of its Shanghai Fast Trak team will be deployed to validate the equipment and provide training for JHL Biotech staff.  After completion, the facility will have a floor space of approximately 2,400 m2 and will contain a number of 2,000L single-use bioreactors.

Source: GE Healthcare

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here